Closer cooperation between the Charité, the Berlin Institute of Health (BIH) and the National Technological Innovation Authority of the State of Israel (Israel Innovation Authority)
The Charité – Universitätsmedizin Berlin, the Berlin Institute of Health (BIH) and the Israel Innovation Authority have signed an agreement sealing their closer cooperation. The partnership will ultimately work towards addressing unmet medical needs and in turn the improvement of patient care. The Israeli Innovation Authority will provide substantial funding for selected projects as well as supporting selected start-ups in the early clinical phase.
The partnership is the result of a longstanding relationship between the Charité and Israel and reflects ongoing efforts to strengthen academic activity via technological innovation. The Memorandum of Understanding celebrated today outlines a pilot program to jointly develop and test effective technologies, products, services and equipment within the Charité and BIH. The pilot program will be launched at the end of 2019 and will offer selected companies a comprehensive, structured program for partnering with the Charité.
"We are very proud of this cooperation! Israel has by far the largest number of start-ups in the world, making it a leading player in Healthcare technology. The program we have developed will help ensure that innovations are swiftly transformed into real benefits for our patients. In other words, this partnership will give true substance to the long revered translational slogan ‘from bench to bedside, from bedside to bench’ ” declared Prof. Dr. Axel Radlach Pries, Charité Dean and BIH Executive Board Chairman.
Speaking at the celebratory event, the Ambassador of the State of Israel in Germany, S.E. Jeremy Issacharoff declared “Germany is Israel's most important trading partner in the European Union. The agreement between the Charité and the Israel Innovation Authority is an important milestone for the strengthening of economic relations between Germany and Israel in the field of medical technology and digital health ". Aharon Aharon, CEO of the Israel Innovation Authority added "The ability to conduct clinical trials and test pilot projects in the world's leading health institutions and clinics is an important step in the development of Israeli start-ups and companies beyond the research and development phase".
Dr. Sein Schmidt
Head of the Clinical Study Center
Campus Charité Mitte
Charité – Universitätsmedizin Berlin
t: +49 30 450 543 537
Back to Overview